NCT07730125尚未招募1 期
Gene-edited T Regulatory Cells (CRG-150) for the Treatment of Relapsed/Refractory Malignancies
CoRegen, Inc.0 个研究点目标入组 67 人开始时间: 2026年11月1日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 尚未招募
- 发起方
- 入组人数
- 67
- 主要终点
- Proportion of patients with DLTs within 28 days from first infusion and overall safety
研究概览
简要总结
The goal of this Phase 1/2a interventional study is to evaluate the safety and tolerability of CRG-150 in relapsed/refractory HR+HER2- breast cancer, Triple Negative Breast Cancer (TNBC) and prostate cancer. The main questions it aims to answer are:
Phase 1
- Incidence of DLTs
- Incidence of CRG-150 related AEs and SAEs
- Select the Recommended Phase 2 Dose (RP2D), as determined through the dose escalation process for the specified indications Phase 2a
- HR+HER2- Breast Cancer and TNBC: Overall Response Rate (ORR) (CR+PR) using FDG PET/CT and RECIST 1.1 by Investigator assessment
- Prostate Cancer: ORR per PCWG3-modified RECIST 1.1 by Investigator assessment
Participants will be required to perform study procedures and assessments, and will also receive the following study treatments:
• CRG-150 cells at the assigned dose
详细描述
This is a first-in-human, open-label, multicenter Phase 1/2a study of CRG-150, an autologous gene-edited Treg cell therapy that will follow a BOIN design of dose-escalating cohorts to determine a Recommended Phase 2 Dose (RP2D). Phase 2a participants will be treated with CRG-150 at the determined RP2D.
Following consent and screening assessments, enrolled participants will undergo an apheresis procedure to manufacture the autologous product. The time from apheresis to delivery of product back to the patient is anticipated to be approximately 28 days, and bridging therapy will be allowed between apheresis and CRG-150 infusion at the Investigator's discretion. No lymphodepleting chemotherapy will be administered prior to CRG-150 infusion.
Participants are followed for disease outcomes for 12 months and for long-term safety for up to 15 years, consistent with FDA guidance.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Sequential
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Capable of understanding, and willing to comply with, and voluntarily sign and date an informed consent form (ICF).
- •Willing to adhere to the study visit schedule and other protocol requirements, including the required apheresis procedure/blood collection.
- •Is ≥18 years old at the time consent is obtained.
- •Must have one of the following metastatic cancer diagnoses:
- •HR+HER2- breast cancer
- •Prostate cancer
- •Has received the following treatment lines for their disease, and in the opinion of the Investigator, the patient would unlikely tolerate or derive clinically meaningful benefit from available treatment options:
- •Metastatic HR+HER2- breast cancer
- •Patients previously treated for metastatic disease with at least two of the following: endocrine therapy (ET), CDK4/6 inhibitors, or antibody-drug conjugate, with disease progression or intolerance to therapy.
- •Prior chemotherapy is not required but does not exclude the patient from the study.
- •Metastatic TNBC (mTNBC, estrogen, progesterone, and human epidermal growth factor receptor 2 [HER2] negative)
- •Patients previously treated for metastatic disease with at least two of the following: immunotherapy, antibody-drug conjugate, or chemotherapy with disease progression or intolerance to therapy.
- •Metastatic prostate cancer (mPC)
- •Previously treated for advanced or metastatic disease with the following, alone or in combination, and have demonstrated disease progression by PCWG3 and/or RECIST 1.1 by Investigator judgment, OR is intolerant to therapy:
- •Patients previously treated for metastatic disease with at least two of the following: androgen deprivation therapy, oral androgen receptor pathway inhibitors, or taxane chemotherapy with disease progression or intolerance to therapy.
- •Patient will be allowed if they refuse or are considered unfit for taxane chemotherapy.
- •Has measurable disease as per RECIST 1.1 or bone-only disease (HR+HER2- breast cancer or TNBC only) OR by RECIST 1.1 or bone-only metastases with measurable prostate-specific antigen (PSA) (≥1 ng/mL) (mPC only).
- •Has an ECOG performance status of 0 or 1 at screening.
- •Has adequate organ function as defined by:
- •Hematological parameters:
- •Absolute neutrophil count (ANC) ≥1.0 × 109/L (1000/µL)
- •Platelet count (PLT) ≥50.0 × 109/L (50,000/µL)
- •Hemoglobin ≥7.0 g/dL
- •Absolute lymphocyte count (ALC) >0.5 × 109/L (500/µL)
- •Renal: Calculated creatinine clearance must be ≥40 mL/min/1.73 m2 (by the Chronic Kidney Disease Epidemiology Collaboration 2021 equation).
- •Hepatic parameters:
- •Serum total bilirubin ≤1.5x upper limit of normal (ULN) (or <3x ULN if liver metastases present or documented Gilbert's Syndrome).
- •Aspartate aminotransferase (AST) ≤2.5x ULN; alanine aminotransferase (ALT) ≤2.5x ULN (AST, ALT ≤5x ULN if liver metastases present).
- •Pulmonary: Oxygen saturation on room air >88% per pulse oximetry and not on supplemental oxygen.
- •Cardiac: Hemodynamically stable and left ventricular ejection fraction ≥45% by echocardiogram (ECHO) or multigated acquisition scan (MUGA).
- •Has met the minimum washout time for previous cancer therapies before apheresis, and in the Investigator's judgment, the patient is able to safely undergo the apheresis.
- •If a woman of childbearing potential (WCBP), defined as a sexually mature woman who has not undergone surgical sterilization or who has not been naturally postmenopausal for at least 12 consecutive months (i.e., who has had menses any time in the preceding 12 consecutive months) must agree to use 2 effective contraceptive methods; examples include oral, parenteral, or implantable hormonal contraceptive, intra-uterine device, barrier contraceptive with spermicide, partner's latex condom or vasectomy) while on study treatment and for at least 1 year after the last dose of the study drug.
- •If a WCBP, she must have a negative serum pregnancy test prior to the dose of the study drug.
- •If male, a patient must agree to use a latex condom, even if he had a successful vasectomy, while on study treatment and for at least 1 year after the last dose of the study drug.
- •If male, a patient must agree not to donate sperm, and if female, a patient must agree not to donate eggs for at least 1 year after the last dose of the study drug.
排除标准
- •On systemic corticosteroid therapy (>5 mg prednisone daily or its equivalent) for an underlying condition (if they were receiving corticosteroid therapy (>5 mg prednisone daily or its equivalent), it must have been stopped >7 days prior to apheresis for cell manufacturing). Note: Use of topical, inhaled, nasal, or ophthalmic steroids is allowed.
- •Previous treatment with any investigational agent within 14 days of Screening Period.
- •Has an active autoimmune disease (including but not limited to systemic lupus erythematosus, Sjögren's Syndrome, rheumatoid arthritis, psoriasis, multiple sclerosis, inflammatory bowel disease) that has required systemic treatment in the past 12 months (i.e., with use of disease-modifying agents, corticosteroids, or immunosuppressive drugs). Replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency) is not considered a form of systemic treatment and is allowed.
- •Active malignancies other than the primary cancer indication, other than non-melanoma skin cancer or carcinoma-in-situ (cervix, bladder, or breast). Patients may be eligible if they have shown no evidence of active disease for two years prior to the first dose of the study drug.
- •Clinically significant, active, uncontrolled, systemic infection; the following are not exclusionary:
- •Patients with human immunodeficiency virus (HIV) must have been on effective antiretroviral therapy for ≥4 weeks prior to enrollment; must have an HIV viral load below the limits of detection; no acquired immunodeficiency syndrome-related opportunistic infections in the past 12 months; and a cluster of differentiation (CD)4+ cell count ≥350 cells/µL.
- •Patients with chronic hepatitis B virus (HBV) infection must be on antiviral therapy and have an HBV viral load below the limits of detection.
- •Patients with chronic hepatitis C virus (HCV) infection must have completed therapy and have an HCV viral load below the limits of detection.
- •Had major surgery (not including placement of vascular access device or tumor biopsies) within 28 days prior to screening, or no recovery from side effects of such intervention, or has planned elective surgery.
- •Presence of active and clinically relevant central nervous system disorder, such as epilepsy, stroke, or symptomatic or uncontrolled brain metastases.
- •Patients with severe chronic diseases of the kidney, liver, heart, lung, or any other serious illness that, in the opinion of the Investigator, may affect the patient's therapies, follow up, or assessments, including but not limited to uncontrolled clinically significant neurological or psychiatric disorders or metabolic diseases.
- •Has significant cardiac disease, such as recent (within 6 months prior to first dose of the study drug) myocardial infarction or acute coronary syndromes (including unstable angina pectoris), congestive heart failure (New York Heart Association class III or IV), uncontrolled hypertension, uncontrolled cardiac arrhythmias, or severe aortic stenosis.
- •Has a history of thromboembolic or cerebrovascular events, including transient ischemic attacks, cerebrovascular accidents, deep vein thrombosis, or pulmonary emboli within 6 months prior to the first dose of the study drug.
- •Patients with deep vein thrombosis or pulmonary embolism initially diagnosed within 6 months prior to the first dose of the study drug may be eligible if they are appropriately treated with anticoagulants (or are off anticoagulants if no longer indicated) and have no evidence of such disease at Screening.
- •Has mental or medical conditions that prevent the patient from giving informed consent or participating in the trial or other severe acute or chronic medical or psychiatric conditions or laboratory abnormality that may increase the risk associated with the study participation or the study drug administration or may interfere with the interpretation of study results and, in the judgment of the Investigator, would make the patient inappropriate for enrollment in this study.
- •Has known or suspected intolerance to the components of the study drug, such as dimethyl sulfoxide.
- •Is concurrently participating in another investigational therapeutic clinical trial.
- •Prior treatment with gene or cell therapy.
- •Is a pregnant or breastfeeding female.
研究组 & 干预措施
Dose Escalation
Experimental
Drug: CRG-150 autologous cell therapy 3 escalating dose levels with 2 de-escalation dose levels are designed to explore the safety, tolerability, cellular kinetics and antitumor activity of CRG-150.
DL-1: 50 x 10e6 cells (de-escalation) DL1: 75 x 10e6 cells DL2: 375 x 10e6 cells DL2.5 (optional): 562 x 10e6 cells (de-escalation) DL3: 750 x 10e6 cells
Phase 2 expansion at RP2D: in HR+HER2- breast cancer, TNBC and/or Prostate Cancer. (10 participants per tumor type)
干预措施: CRG-150 (Drug)
结局指标
主要结局
Proportion of patients with DLTs within 28 days from first infusion and overall safety
时间窗: *DLTs: within 28 days from first cell infusion. *Incidence of AEs: Up to 15 years *Incidence of SAEs: Up to 15 years
* The proportion of patients with DLTs occurring within 28 days from first cell infusion will be calculated for each dose level * Overall safety: type, frequency, and severity of SAEs (IRRs, immune reactions, new malignancies, AEs leading to death, and DLTs), and of treatment-related AEs and systemic reactions
Determine the recommended phase 2 dose (RP2D) of CRG-150
时间窗: Up to 1-year post-infusion
RP2D, as determined through the dose escalation process for the specified indications
次要结局
- Cellular Kinetics: Presence, frequency, persistence and expansion of CRG-150 after infusion, by ddPCR(Expansion up to 12 months post-infusion with CRG-150; Persistence: up to 5 years after infusion with CRG-150)
- Efficacy: ORR in r/r HR+HER2- breast cancer and TNBC(Up to 12 months post-infusion of CRG-150)
- Efficacy: ORR in r/r prostate cancer(Up to 12 months post-infusion with CRG-150)
研究者
相似试验
尚未招募
1 期
A Study Evaluating the Immunotherapy Treatment for Ovarian Cancer and Other Advanced Malignancies.Ovarian CancerNCT07389239University of Chicago24
尚未招募
1 期
TCR-T Cell Therapy for KRAS Mutation in Advanced Solid TumorsNCT07342738Sun Yat-sen University25
尚未招募
1 期
Phase 1b Study Of TRICK-NK In Combination With T-Dxd In Treatment-Refractory Breast CancersBreast CancerNCT07553390M.D. Anderson Cancer Center60
尚未招募
1 期
Phase 1/2 Window Of Opportunity Study Of TROP2 CAR/IL-15 TGFBR2 KO NK Cells Delivered Intraperitoneally For The Management Of Gastric Cancer Metastatic To The PeritoneumNCT07509008M.D. Anderson Cancer Center10
尚未招募
2 期
Naive T Cell Deplete Grafts for GVHD Prevention in Non-Malignant DiseasesBone Marrow FailureHemoglobinopathiesPrimary Immune Deficiency (PID)Autoimmune CytopeniaImmune DysregulationHemophagocytic Lymphohistiocytosis (HLH)Non Malignant DisordersNCT07660783Fred Hutchinson Cancer Center40